SOBI completed the acquisition of the emapalumab business from Novimmune for $519m.

SOBI, a rare disease specialist, completed the acquisition of the emapalumab business from Novimmune, a pharmaceutical company, for $519m. “The acquisition of emapalumab and related assets is an important step in the transformation of Sobi in becoming a global leader in rare diseases. This will allow us to realise the full potential of emapalumab as an important treatment in the area of Immunology and address a significant unmet medical need." Guido Oelkers, Sobi President and CEO.